
Opinion|Videos|December 4, 2024
Case 1: Metastatic Castration- Sensitive Prostate Cancer (mCSPC)
Key Takeaways
Panelists discuss how the management of metastatic castration-sensitive prostate cancer involves a multidisciplinary approach, utilizing androgen deprivation therapy, chemotherapy, and novel agents to control disease progression and improve patient survival.
Advertisement
Episodes in this series
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Suzanne Merrill, MD, on recent progress with immunotherapy in bladder cancer
2
LUGPA 2025: Staying the course for independent urology practices
3
How the SURE procedure boosts efficiency in treating stones
4
Scott Sellinger, MD, FACS, highlights 2025 LUGPA Annual Meeting
5
















